Importantly, we observed efficient killing of CSPG4-expressing chondrosarcoma cells in vitro when incubated with CSPG4-targeted CAR T cells demonstrating that CSPG4-targeted CAR T cell immunotherapy may be an effective adjuvant therapy in CSPG4-positive conventional and dedifferentiated chondrosarcoma tumors. This evidence concerns the gene CSPG4 and chondrosarcoma.